Showing results (2011-2020 of 2,093) with videos related to
Sort By:
Pageof 210
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic SarcomasBreelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.AIDS and Behavior|September 8, 2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIVJessica J Wyse, Kathleen A McGinnis, E Jennifer Edelman, et al.Science (New York, N.Y.)|December 15, 1989
Plasma observations near neptune: initial results from voyager 2J W Belcher, H S Bridge, F Bagenal, et al.Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|April 16, 2010
The Canadian STOP-PAIN project - Part 1: Who are the patients on the waitlists of multidisciplinary pain treatment facilities?Manon Choinière, Dominique Dion, Philip Peng, et al.AIDS and Behavior|September 20, 2021
Change in Alcohol Use Based on Self-Report and a Quantitative Biomarker, Phosphatidylethanol, in People With HIVKathleen A McGinnis, Janet P Tate, Kendall J Bryant, et al.Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|April 24, 2010
The Canadian STOP-PAIN project - Part 2: What is the cost of pain for patients on waitlists of multidisciplinary pain treatment facilities?Denise N Guerriere, Manon Choinière, Dominique Dion, et al.Journal of Child Neurology|February 12, 2008
Genetic and clinical heterogeneity in eIF2B-related disorderJelena Maletkovic, Raphael Schiffmann, J Rafael Gorospe, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumorsGeoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.Pageof 210